Sartan contaminant recall hits generics manufacturers
By 
Kit Chapman2021-06-29T09:07:00
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
Three generics manufacturers have recalled dozens of batches of high blood pressure medication across Europe following detection of an impurity in a common active pharmaceutical ingredient (API).
Bristol Laboratories, Brown & Burk and Teva issued the recall of irbesartan and losartan, both angiotensin II receptor blockers, following detection of 5-(4’-(azidomethyl)-[1,1’-biphenyl]-2-yl)-1H-tetrazole (AZBT), which may increase a patient’s risk of cancer over time.